Drug intelligence / Profile preview

SCY-641

Development stage: Discontinued
Lead developer: Scynexis
Modality: Peptides, Small Molecules
Administration: Ophthalmic

Overview

SCY-641 is a cyclophilin inhibitor and cyclosporine derivative developed by SCYNEXIS. It was primarily investigated for the treatment of ophthalmic diseases, specifically keratoconjunctivitis sicca (KCS or "dry eye") in dogs. The compound was licensed to Dechra Pharmaceuticals for worldwide animal health applications in 2012, but the agreement was terminated in 2015 (effective May 2016), with all rights returning to SCYNEXIS. SCY-641 is part of SCYNEXIS's cyclophilin inhibitor platform, which also includes SCY-635. The drug's development was supported by a Qualifying Therapeutic Discovery Project (QTDP) grant from the U.S. Federal Government for its potential in treating ophthalmic diseases.

Other names: cyclosporine derivative

Beyond the preview

Go deeper on SCY-641.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCY-641.

Explore the full profile